PDGFRA and Kaposi's sarcoma: The anti-PDGFRA antibody (Lartruvo/ Olaratumab) acts by blocking the interaction of PDGFs with PDGFRA and has been shown to add a significant benefit to patients receiving only doxorubicin, which in its liposomal form (Doxil) is a frontline therapy to AIDS-KS.